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Some Biochemical Changes Associated with Taking  Oral 
Contraceptive Pills Among Healthy Women in Gaza City 
 
ABSTRACT
Aim: To evaluate some biochemical changes associated with oral contraceptive (OC) 
pills  administration on healthy women in Gaza City (GC). 
Methodology: The study design was a case control. The sample size was 80 healthy 
women aged 20-35 years from the Swidey Clinic who had taken OC pills for at least  
three continuous cycles. The control sample was healthy married women who were not 
going on OC before and match the cases in age and residence. The study questionnaire 
included issues about the following information: age, gender, weight, height, health 
history, blood pressure, Nature of menstrual cycle, bleeding, insomnia, pain in the 
stomach, difficulty in breath, pain in hands and feet, appetite and headaches. 
Blood parameters analysis of the study population included complete blood count 
(CBC), C-reactive protein (CRP), high density lipoproteins cholesterol (HDL-C), low 
density lipoproteins cholesterol (LDL-C), total cholesterol (TC), and triacylglycerol 
(TAG). Leptin determination was carried out using a commercially available diagnostic 
system test kits. SPSS were used to analyze obtained data. 
Results: The results showed statistically significant differences among study population 
with respect to regular of menstrual cycle (MC) (2=5.371, P= 0.024), increased 
appetite (2= 4.386, P= 0.002), increased headache (2= 6.82, P= 0.000), increased 
body mass index (2= 7.31, P= 0.015), cholesterol were significantly higher among the 
cases compared to control (179.1± 4.3mg/dl vs 157.5± 4.12mg/dl, and p=0.000), LDL-
C were significantly higher among the cases compared to control (97.6±3.8mg/dl vs 
86.2± 3.4 mg/dl, and p=0.002), increased C-reactive protein (2= 5.381, p= 0.034), 
there were a significant increase in the mean level of leptin among the cases compared 
to the controls  (36.3± 2.3 ng/ml vs. 28.6± 2.1 ng/ml, and p= 0.003), and the levels of 
WBC, Gran and Mch were significantly higher among the cases (7.2±2.1 K/µL, 
60.7±8.3 % and 26.9±2.2pg) compared to the controls (6.6±1.7 K/µL, 54.9±11.7 % and 
25.7±3.4 pg), with p=0.001, p=0.000 and p=0.003, respectively. In contrast, the results 
 v
showed no statistically significant differences among the study population with respect 
to frequency of bleeding (2=0.192, P=0.135), frequency of insomnia (2=0.411, 
P=0.353), pain in stomach (2=0.386, P=0.183), difficulty in breathing(2=0.497, P= 
0.209), frequency of pain in hands and feet (2=0.631, P= 0.309), Systolic blood 
pressure ((2=2.351, P=0.139 ), diastolic blood pressure (2=1.372, P=0.382 ), HDL-c 
(51.2±1.7mg/dl vs 47.6±1.3mg/dl and p=0.148), TAG (119.2± 6.0mg/dl vs 108.2± 8.6 
mg/dl and p=0.218), the changes among the study population in Mid, RBc, Hb, Hct, 
Mcv, Mchc and PLt (7.8±8.7 %, 4.6±0.7M/µL,12.2±0.9g/dl, 38.0±2.4%, 80.8±11.9fl, 
32.5±1.1g/dl and 279.3±87.6K/µL) compared to control were not significant (8.6±6.6 
%, 4.6±0.47M/µL, 12.3±1.1g/dl, 37.5±3.7%, 80.6±8.5fl, 32.3±1.7g/dl and 267.8±74.0 
K/µL), with p=0.352, p=0.394, p=0.387, p=0.571, p=0.415, p=0.272 and p=0.185, 
respectively.  
Moreover, the results showed strong correlation between BMI and leptin (p= 0.000) 
among the study population. 
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1.1 Overview  
Oral contraceptives (OCs) are the most popular type of birth control pills. The pills stop 
ovulation, preventing the ovaries from releasing eggs. they also thicken cervical mucus, 
making it harder for sperm to enter the uterus (Feminist Women's Health Center, 2008).                                       
Obesity, breakthrough bleeding, nausea, high blood pressure (hypertension), high 
cholesterol, signs of a blood clot and bloating are some of the more commonly reported 
OC pills side effects ( Bakir and Hilliquin, 1986). On the other hand, OC  increases a 
woman's risk to cerebrovascular disease and cervical cancer. A woman taking the pill is 
1.9 times more likely  to die from cerebrovascular disease and 2.5 times more likely to 
die from cervical cancer (Life Site News, 1999). Oral contraceptives are taken by about 
100 million women worldwide. Studies have shown that synthetic hormones used for 
OC greatly increased the risk of blood clotting. Clots typically form in the legs and can 
cause serious injury and death if they travel to the heart, lungs or brain (Baklinski, 
2008). 
High body weight could be also a side effect of OCs. Leptin's effects on body weight 
are mediated through effects on hypothalamic centers that control feeding behavior and 
hunger, body temperature and energy expenditure. It  is a protein hormone with 
important effects in regulating body weight, metabolism and reproductive function. 
Leptin also acts as appetite suppressant. It stops eating too much as well as makes  the 
body more active so it burns off more energy.  The amount of leptin found in people 






1.2 Significance and general objectives     
Although OC pills are usually used elsewhere since very long time, no studies were 
carried out about impact of OCs on healthy women in Gaza Strip. The general objective 
of this study, therefore, is to evaluate some biochemical changes associated with taking 
OC pills on healthy women in Gaza City. 
 1.3 Specific objectives 
1- To define some side effects of OC pills administration. 
2- To assess the effect of OC pills administration on serum leptin level as a marker of 
obesity.  
3-To determine changes in serum level of cholesterol, HDL-C, LDL-C and TAG, C-
reactive protein associated with OC pills administration. 
4- To determine effect of OC pills  on some blood parameters 












2.1 Types of oral contraceptives                                                     
2.1.1 Combination  oral contraceptives 
Combination OCs contain both estrogen and progesterone. Combination birth control 
pills may be monophasic, where each of the active pills contains the same amount of 
estrogen and progesteron, or biphasic, where the active pills contain varied amounts 
of hormones designed to be taken at specific times throughout the pill-taking schedule 
(National Women's Health Resource Center Inc, 2009). Synthetic hormones are used 
in OCs estrogens, such as,  mestranol, ethinyl estradiol (EE). Progesterones used in 
OCs are synthetic progesterones, such as norethindrone, norgestrel, norethindrone 
acetate, ethynodiol diacetate, levonorgestrel, norgestimate, desogestrel, drospirenone. 
Different progesterons have different strengths and side effects (Watson Pharma Inc, 
2006).   
                                                           
2.1.2 Progesterone-only oral contraceptives 
This type of pill contains no estrogen, called the progesteron-only pill, or "mini-pill, 
it's for breastfeeding women because estrogen reduces milk production (National 
Women's Health Resource Center Inc, 2009). It also will be taken if women  are 
hypertensive, or at risk for developing blood clots. Minipills are slightly less effective 
than regular pills and often cause irregular menstrual patterns. Minipills prevent 
pregnancies mainly by making the cervical mucus impermeable to sperm and by 
making it more difficult for an egg to attach to the uterus lining ( Watson Pharma Inc, 
2006).  
Causes of bleeding  
In 1982, more than 20% of women surveyed in a nationally representative sample had 
discontinued OCs on their own or at the recommendation of their physician due to 
bleeding or spotting.   
 ϰ
Bleeding may be due to: 
1) physiologic effects of OCs on the endometrium. 
2) Oral contraceptive-related parameters, including dose and formulation.  
3) patient behavior, including compliance, using concomitant medications, and 
smoking.  
4) benign or malignant pathology (Goliath service, 2008).   
                                                                                
2.1.3 Pharmacological classification  
First generation OCs contain  high dose ( > 50 mg) of ethinyl estradiol (EE).  
Second generation OCs contain levonorgestrel, norgestimate, norethindrone family 
and 30-35 mg EE .        
Third  generation OCs contain desogestrel or gestodene and <30 mg EE  (Jessica and 
Lalley, 2000). 
 
2.2 Mechanism of action of oral contraceptives 
The pituitary gland produces two hormones called Follicle Stimulating Hormone 
(FSH) and Luteinizing Hormone(LH). These hormones stimulate the ovary to produce 
an egg each month. The ovary is the site of production of the woman's two central 
female hormones, estradiol (EST), a type of estrogen, and progesterone (PRO), a type 
of progestin. Oral contraceptive pills are a combination of synthetic estrogen and 
progesterone. They causes negative feedback decreases in the pulse frequency of 
gonadotropin-releasing hormone (GnRH) release by the hypothalamus, which 
decreasing the release of FSH and greatly decreases the release of LH by the anterior 
pituitary (Figure 1). These two hormones are needed for ovulation to occur, therefore, 
OCs suppress, but do not eliminate ovulation.                                                                                                             
The progesterone component of the combination pill also causes the inner lining of 
the uterus to become thin and shriveled, unable to support implantation of the embryo. 
 ϱ
Mucus cervix thickens under the influence of a progesterone impedes sperm 









Figure 1: Gonadotropic hormones action and regulation (Bowen, 2004). 
2.3 Side effects of oral contraceptives  
2.3.1 Blood pressure: Women taking OCs could have an increase in both systolic 
blood pressure (SBp) and diastolic blood pressure (DBp). Early results from a 
controlled long-term prospective study have shown no significant change in mean 
systolic or diastolic pressures or mean weight in 31 women after four months on OCs. 
However, there was a significant change in Bp or weight over the short period of the 
experiment (Weir et al., 1969). 
Calvin et al., (1969) examined the relation between use of OCs and Bp in 1,575 white 
working females aged 15 to 44 years. Of these, 31.5% were using OCs when their Bp 
was measured. Results analysis revealed slightly higher and statistically significant 
mean SBp and DBp in women using OCs, after correction for age, height, weight, and 
arm circumference. A sample of this population one year later, showed little tendency 
for Bp to be affected by OCs, except for a slight but significant fall in DBp among 
women who did not use these drugs.  
 ϲ
Fisch et al., (1977) study on 13,358 women showed that OC use is associated with a 
slight but statistically significant (P <.05) rise in mean Bp. The age-adjusted 
proportion of OC users with a Bp over 140/90 mm Hg was about three times that of 
nonusers. Women continuing OC use had no appreciably greater change in Bp 
between users and nonusers. 
Khaw and Peart, (1982) examined the relation between OCs and Bp in 461 women. 
The result showed that significantly higher mean systolic and diastolic blood 
pressures than those using non-hormonal contraception. There was a significant 
correlation of blood pressure with duration of current use of OCs but not with total 
duration of use. There was also a significant negative correlation of blood pressure 
with time since OCs were last taken, and women who had stopped using oral 
contraceptives over a month previously had similar blood pressures to those who had 
never taken them. In women taking OCs had either a history of hypertension in 
pregnancy or a family history of hypertension had significantly higher mean blood 
pressures than those who did not. 
Wei , (1997) assessed whether the blood pressure is higher among women who take 
OCs than it is among those who do not.A cross-sectional survey of a stratified 
random sample of English adults (aged ≥ 16 years), sample of english adults, 3545 
premenopausal women, of whom 892 were current users of OCs. Mean blood 
pressures adjusted for age were significantly higher among oral contraceptive users 
(125/70 mmHg) than they were among non-users (123/68 mmHg, P < 0.001 both for 
systolic and for diastolic blood pressures). These results remained unchanged after 
further adjustment for the body mass index, alcohol intake, physical activity and 
hypertension treatment. Blood pressure differences tended to be larger among older 
oral contraceptive users. Oral contraceptives containing progestogen only were not 
associated with higher blood pressures.Blood pressures should be screened before 
OCs are supplied and should be monitored regularly during oral contraceptive use. 
Bertschi et al., (2003) assessed the systemic and renal hemodynamic and tubular 
responses to salt in 27 young healthy women taking OCs  containing monophasic 
combination of 30g EE and 150g desogestrel for >6 months. All women were 
assigned at random to receive a low (40 mmol/day) or a high (250 mmol/day) sodium 
diet for 1 week on two consecutive menstrual cycles during the active OC phase. At 
 ϳ
the end of each diet period, 24-hour Bp, renal hemodynamics, sodium handling, and 
hormonal profile were measured, The use of OCs is not associated with an increase 
Bp response to salt, however, OCs affect the renal hemodynamic response to salt, a 
high salt intake leading to an increase in glomerular filtration rate (GFR) and filtration 
fraction. This effect is possibly mediated by the estrogen-induced activation of the 
renin-angiotensin system. Oral contraceptives also appear to increase the tubular 
responsiveness to changes in sodium intake. This indicated that synthetic sex steroids 
have a significant impact on renal function in women. 
 
2.3.2. Change of lipid profiles 
Doar et al., (1969) studied the effects of OCs on fasting serum lipid levels in two 
groups of women. One hundred and twenty-eight subjects (group A) were tested 
before and during therapy; 52 subjects (group B) were tested initially during therapy 
and again after this had been discontinued. In both groups OC therapy was associated 
with significantly raised mean serum triacylglycerol (TAG) and total cholesterol (TC) 
levels. A significant elevation of the mean fasting serum TAG level was also found in 
a group of 19 women receiving low-dose glucocorticoid therapy, though the 
percentage increase (16%) was less than that in the women receiving OCs (49%). 
Narboni et al., (1978) investigated a systematic treatment for patients on OCs in 
whom hyperlipidism is induced by the OCs. Thirty six women aged 20-40 years who 
used OCs containing 50 mcg of EE and Norgestrel were included in the study. Nine of 
them women had elevated TAG levels, 5 had elevated TC levels, and 22 had both. 
The average level of TAG was 1.56 and of TC was 2.88 g/l. When the EE dosage of 
the 1st group was reduced to 30 mcg, the average TAG level fell from 1.44 to l g/l. In 
a 2nd group, in which either lipid levels were very high, the use of combined OCs was 
discontinued; the average level of TAG declined from 1.64 to 0.95g/l.  
Hennekens et al., (1979) measured fasting plasma TAG, plasma TC and HDL-C 
cholesterol levels for 190 white women, ages 21--39 years, who used OCs. The mean 
level of fasting TAG was higher among current OC users (95 mg/100 ml) than among 
nonusers (73 mg/100 ml) (p = 0.002). After adjustment for the possible confounding 
effects of age, weight, current cigarette smoking and fasting glucose level, current OC 
users still had a mean plasma TAG level 19 mg/100 ml higher than that of nonusers (p 
 ϴ
= 0.007). Current OC users also appeared to have higher levels of TC. There was a 
nonsignificant inverse relationship of OC use with HDL cholesterol levels. 
Parks et al., (1989) studied the effect of two different combination OCs  steroid 
preparations containing equivalent amounts of estrogen but different progesterone 
components on plasma lipids and lipoproteins. For 2 years, one group (n= 23) 
received 75 micrograms norgestrel and 7.5 micrograms EE daily, while another group 
(n = 25) received 150 micrograms ethynodiol diacetate and 7.5 micrograms EE daily. 
The control group n = 24 received no treatment. The result of the study showed that 
the two oral contraceptive groups had higher TC and TAG concentrations compared 
to control group. 
Willy et al., (1990) studied the effects of OCs on serum lipids and blood pressure 
were among young women in the Netherlands. Fifty-three participants, ages 14 to 24 
years. They continued OCs use for at least 2 subsequent years. From 53 age-matched 
control subjects, who did not use OCs, data were obtained for the same follow-up 
period. Women using oral contraceptives showed a significantly greater rise in serum 
total cholesterol levels than did the reference subjects (14 mg/100 ml/2 year vs 4 
mg/100 ml/2 year; 95% confidence interval of the difference was 0.1 to 19.6). The 
increase in systolic blood pressure (4.7 mm Hg/2 year vs 2.1 mm Hg/2 year; 95% 
confidence interval of the difference was −1.8 to 6.9) did not differ between the 
groups. These findings suggest that OCs use may be associated with an enhanced rise 
in total cholesterol during adolescence.                                                                                                                    
Emokpae et al., (2010) studied the effect of duration of oral contraceptive use on lipid 
and lipoproteins in Nigerian women. One hundred and twenty women (mean age 
24.1±5 years) were used who were on biphasic lofeminal tablets for a period ranging 
from 1- 48 months. Fifty age matched women with regular menstruation with no 
history of hormonal use within the last six months before the investigation were used 
as controls. Statistically significant increases were observed for TAG, LDL-c, and 





2.3.3 Inflammatory diseases  
C-reactive protein (CRP) is produced by the liver. The level of CRP rises when there 
is inflammation throughout the body (Ridker et al., 2007). High or increasing amount 
of CRP blood suggests that there is an acute infection or inflammation. CRP levels 
can be elevated in the later stages of pregnancy as well as with use of birth control 
pills or hormone replacement therapy (i.e., estrogen). Higher levels of CRP have also 
been observed in the obese individual (American Association for Clinical Chemistry, 
2009).                                                                                                       
Swan, (1991) provided the data on hospital admission and death rates in relation to 
the use of OCs in a large suburban population which has been followed up for 10 
years. The incidence of hospital admission for inflammatory disease was significantly 
increased among women under age 40 who had ever used OCs, and the systems 
affected include the respiratory, digestive, urogenital, and musculoskelatal. The 
relative risk for such a hospital admission is 2.8 in past OC users and 1.8 in current 
OC users. This effect is considerably reduced in older users. A systemic increase in 
the risks of inflammatory disease resulting from OC use is consistent with a 
modification of the immune system. The author also observed an increase in white 
blood cell count among OC users. 
Dreon et al., (2003) found that plasma CRP levels were two times higher among OC 
users than among non-users (2.0 ± 0.2 versus 0.9 ± 0.3 mg/l, p < 0.0001) independent 
of diet. The results suggested that estrogenic hormones significantly affect pro-
inflammatory pathways.  
Wanpen Vongpatanasin et al., (2003) demonstrated that OCs caused a sustained 
increase in CRP, implicating a pro-inflammatory effect. Because CRP is synthesized 
in the liver, they hypothesized that estrogen-induced CRP elevation is related to first-
pass hepatic metabolism. 
Cauci et al., (2008) observed an increase in low-grade inflammatory status measured 
by high-sensitivity CRP concentrations in response to OCs use. Alteration of 
 ϭϬ
inflammatory status in OC users could affect the risk of venous thromboembolism, 
cardiovascular disease, and other oral contraceptive-associated adverse conditions in 
young women. 
Life Site News (2008) concluded that the OCs elevates the levels of  CRP in women, 
which raises the risk of cardiovascular disease. In comparing healthy women who 
used the pill with a group that didn't, the study found that pill-users were more than 
four times more likely to have high levels of CRP in their bodies which leading to a 
high risk of cardiovascular disease. 
 
2.3.4 Cardiovascular diseases 
There is an association between OCs use and cardiovascular disease (CVD). It is 
thought that the hormones contained in the OCs formulas create an environment 
which affects the clotting cascade by altering clotting factors. Blood clots form, 
dislodge, and block arteries and veins of the heart or the brain, interrupting the blood 
supply and causing a heart attack or stroke. Estrogen affects events in the arteries and 
veins. Progesterones affect events that take place in the arteries only. The levels of 
clotting factors, such as fibrinogen, and cholesterol in the blood have been related to 
the risk of CV events. Oral contraceptives users had more fibrinogen, factor VIIc and 
factor XII (Hageman factor) than nonusers. Furthermore, the more estrogen contained 
in the OCs formula, the more the clotting factors are increased, it is highly likely that 
the same mechanism is at work in women taking OCs. Kelleher, (1998) reported that 
women who are taking OCs are at risk for CV events through changes in the clotting 
process, leading to thrombosis. Women who use birth control pills are at a slightly 
increased risk of having a blood clot in the legs or lungs. Studies consistently showed 
that the risk of venous thromboembolism is two to six times higher in OCs users than 
in nonusers. The risk of blood clots is highest in women with clotting disorders or 
who have previously had a deep venous thrombosis or pulmonary embolism. Other 
risk factors of CVD include: obesity, older age, having several family members 
who've had blood clots before old age, air travel, and having to lie or sit for a 
prolonged period (Birth Control Pills Advantages and Disadvantages, 2007).  
 ϭϭ
However, the chances of OCs contributing to a heart attack are small except with 
smoking. Studies have shown that smoking dramatically increases the risk of heart 
attack in women administration Ocs aged 35 years or older (Women's Health, 2004). 
 
2.3.5 Obesity 
Body mass index  is a common measure expressing the relationship (or ratio) of 
weight-to-height. It is a mathematical formula in which a person's body weight in 
kilograms is divided by the square of his or her height in meters i.e. wt/(ht)2.. The 
BMI is more highly correlated with body fat than any other indicator of height and 
weight. Individuals with a BMI of 25 to 29.9 are considered overweight, while 
individuals with a BMI of 30 or more are considered obese (National Research 
Council, 1989).  
Obesity is an excessively high amount of body fat or adipose tissue in relation to lean 
body mass. The amount of body fat (or adiposity) includes concern for both the 
distribution of fat throughout the body and the size of the adipose tissue deposits 
(Stunkard and Wadden, 1993).  
Hirschberg et al., (1996) investigated the role of the "satiety peptide" cholecystokinin 
and some other gastrointestinal hormones among 10 young healthy women taking 
OCs. A standardized meal test was used for recordings of appetite and gastrointestinal 
hormone response before and after 5 months of treatment with a monophasic 
combined OCs. Oral contraceptivs caused a suppression of basal levels of serum 
cholecystokinin, which was correlated to an increase in body fat. Serum levels of 
gastrin and insulin were also unchanged, whereas TAG and postprandial glucose 
levels were elevated. Therefore reduced cholecystokinin levels may be related to mild 
impairment of glucose tolerance and promote body fat storage during OCs. 
A combination of medical disorders of OCs includes: diabetes mellitus type 2, high 
blood pressure, high blood cholesterol, and high triglyceride levels (Grundy, 2004). 
Due to OCs, the level of metabolism alters. This is because both the estrogen and 
progesterone present in these pills can cause fluid retention, a temporary effect that 
often begins in the first month as a result of an increase in sodium. The cause of 
weight gain (increase of hips, breast, or thigh) is due to estrogen. Oral contraceptives 
 ϭϮ
contain progesterone which cause increase in appetite and permanent weight gain 
(Crystal, 2005).   
Obesity increases the risk of many physical and mental conditions. These 
comorbidities are most commonly shown in metabolic syndrome, Certain medications 
may cause weight gain or changes in body composition, these include:  insulin, 
steroids, some forms of hormonal contraception and so on (Haslam and James., 2005). 
Coronary artery disease, fatty liver, gall stones, sleep apnea, arthritis, and cancer may 
shorten the lifespan (Ogden et al., 2007).                                         
Syed et al., (2008) studied the CVD risk factors in users of second generation 
contraceptives by measure changes in BMI, blood pressure and electrocardiogram. 
Sixty four women volunteered for this study (age range 20-35 years). Results showed 
that women aged less than 30 years and using OCs for more than three years had a 
tendency to gain weight and increase in systolic and diastolic blood pressures. World 
Health Organization (2009) reported that obesity and overweight pose a major risk for 
chronic diseases, including type 2 diabetes, cardiovascular disease, hypertension and 
stroke, and certain forms of cancer. 
                                                                                 
2.3.6Change in leptinlevel 
Leptin (Greek leptos meaning thin) is a 16 KDa protein hormone that plays a key role 
in regulating energy intake and energy expenditure, including appetite and 
metabolism. It is one of the most important adipose derived hormones (Brennan and  
Mantzoros, 2006). The Ob (Lep) gene (Ob for obese, Lep for leptin) is located on 
chromosome 7 in humans (GreGreen et al., 1995). In addition to white adipose tissue, 
leptin can be produced by brown adipose tissue, placenta (syncytiotrophoblasts), 
ovaries, skeletal muscle, stomach (lower part of fundic glands), mammary epithelial 
cells, bone marrow, pituitary and liver (Margetic et al., 2002). 
Leptin interacts with different types of receptors (Ob-Ra-Ob-Rf, or LepRa-LepRf) 
which in turn are encoded by a single gene, LEPR (Wang, 1996). Ob-Rb is the only 
receptor isoform that can signal intracellularly via the Jak (Janus-Activated Kinase) -
Stat (Signal Transducer and Activators of Transcription) and MAPK (Mitogen-
activated protein kinases) signal transduction pathways and is present in hypothalamic 
 ϭϯ
nuclei (Malendowicz et al., 2006). It is unknown whether leptin can cross the blood-
brain barrier to access receptor neurons, because the blood-brain barrier is somewhat 
absent in the area of the median eminence, close to where the Neuropeptide Y (NPY) 
neurons of the arcuate nucleus. It is generally thought that leptin might enter the brain 
at the choroid plexus, where there is intense expression of a form of leptin receptor 
molecule that could act as a transport mechanism. 
Once leptin has bound to the Ob-Rb receptor, it activates the stat3, which is 
phosphorylated and travels to the nucleus to, presumably, effect changes in gene 
expression. One of the main effects on gene expression is the down-regulation of the 
expression of endocannabinoids, responsible for increasing appetite. There are other 
intracellular pathways activated by leptin, but less is known about how they function 
in this system. In response to leptin, receptor neurons have been shown to remodel 
themselves, changing the number and types of synapses that fire onto them (Margetic 
et al., 2002). 
Rechberger et al., (1999) investigated serum leptin concentrations in women taking 
OCs containing the same OCs. Thirty women taken 20 microg of EE and 150 microg 
of desogestrel, second group of 30 women received 30 microg of EE and 150 microg 
of desogestrel. Serum leptin concentrations after the first day of the cycle prior to the 
onset of therapy as well as after the 3rd and 6th treated cycles were measured. In both 
groups a positive correlation between serum leptin and BMI was found (r=0.56; 
P<0.001 and r=0.67; P<0.001). The initial serum leptin concentration in the first 
group was 7.62+/-8.46 ng/ml. This value was not statistically different from values 
after 3 months (9.31 +/-8.23 ng/ml) and after 6 months (10.53+/-8.03 ng/ml) of 
treatment. Very similar results were found in patients of second group: 8.81+/-6.56 
ng/ml initially; 11.62+/-11.16 ng/ml at 3 months, and 10.38+/-7.32 ng/ml at 6 months. 
  
2.3.7 Other side effects 
Some other important OCs side effects have been also reported by different sources 
(Women's Health, 2004; Birth Control Pills Advantages and Disadvantages, 2007; 
National Women's Health Resource Center Inc, 2009) which are:  
 ϭϰ
 Migraines and stroke: Women who take OCs and have a history of migraines 
have an increased risk of stroke.                                          .                                                                                                                 
 Headaches: Headaches may start in women who have not previously had 
headaches. 
 Depression: Depression (sometimes severe) and other mood changes may 
occur. 
 Nausea and vomiting. 
 Bleeding or spotting: Spotting or bleeding between menstrual periods is very 
common in the first cycle of pills. 
 Chloasma (spotty darkening of the skin on the face): Darkening of the skin on 
the upper lip, under the eyes, or on the forehead (chloasma).  
 Diarrhea or vomiting: Anything that makes the pill go through your system too 
fast can make the pill not work as well because it was not absorbed or, worse, 
if it is lost in the vomit  
 Worsen severe diabetes: The estrogen in OCs may increase glucose levels and 
decrease the body's insulin response, while the progesterone in the pills may 
encourage overproduction of insulin.  
 Possible acceleration of gallbladder disease. Estrogen may cause bile to 
become oversaturated with cholesterol, which can lead to gallstones. 
 No decreased risk of sexually transmitted infections. Oral contraceptives do 
not protect against sexually transmitted diseases.  
 Cancer of the breast or reproductive tract, liver problems or cancer,  






Materials and Methods 
3.1 Study design: The study design was a case control. 
3.2 Target population: The target population is healthy women aged 20-35years in 
Gaza City. 
3.3 Setting of the study: The present study was carried out on women attending the 
Swidey family control clinic in Gaza City.  
3.4 Sample size: The experimental sample size was 80 healthy married women aged 
20-35 years from the Swidey Clinic who had taken OC pills for at least  three 
continuous cycles. The control sample was healthy married women who were not 
going on OC before and match the experimental sample in age and residence. 
3.5 Tools of the study: The questionnaire included issues about the following 
information: age, gender, weight, height, health history, blood pressure, nature of 
menstrual cycle, bleeding, insomnia, pain in the stomach, difficulty in breath, pain in 
hands and feet, appetite and headaches. 
 3.6 Exclusion and inclusion criteria 
3.6.1 Exclusion criteria 
1- Nursing mother   
2- Going on regime 
3- Going on exercise 
4- Diabetic woman 
5- Any woman taking OC less than three frequent menstrual cycle (MC). 
 
3.6.2 Inclusion criteria 
1- Married woman aged 20-35 years who are living in Gaza City. 




3.7 Blood sampling and processing: About 6 ml fasting blood were collected from 
each women in the  study sample.  About 4 ml of the blood were collected in a tube 
without anticoagulation. Then, serum samples were be obtained by centrifugation at 
3000 rpm for 20 min. The separated serum was be divided into two plastic tubes. One 
sample was stored at 2-5˚C for no more than 24 hours prior to blood parameters 
analysis, and the other was stored at -70˚C for leptin determination. The remainder 
quantity of the blood (2ml) was placed into EDTA tube to perform CBC test, using 
Cell-Dyn 1800.  
3.8 Blood parameters analysis: Blood parameters analysis including CBC, CRP, 
HDL-C, LDL-C, cholesterol and TAG were carried out using a commercially 
available diagnostic system test kits (Friedewald et al., 1972; Deeg and Ziegenhorn, 
1983).   
Calculation of colorimetric tests for CBC, CRP, cholesterol, TAG were performed 
by the autoanalyzer automatically according to beer's law after calibration and 
adjustment of the photometers against water blank using a specific program of every 
test inserted to the instrument. 
The concentration of colorimetric test =           A Test x C CALS 
                                                                               A CALS 
Serum high density lipoprotein cholesterol (HDL-C) was determined 
spectrophotometrically and then low density lipoprotein cholesterol (LDL-C) value 
were determined, using specific formula (shown in page 19). 
 
3.8.1 Determination of serum cholesterol 
Serum cholesterol was determined by cholesterol oxidase (COD)/POD method 
(Meiatlini et al., 1978) using BioSystems kit, Spain. 
Principle 
Free and esterified cholesterol in the sample originates, by means of the coupled 
reactions described below, a colored complex that can be measured photometrically. 
 ϭϳ
Cholesterol ester + H2O       
Cholesterol Esterase       Cholesterol + Fatty acid 
 Cholesterol + 1/2 O2 + H2O         
COD         Cholestenone + H2O2 
2 H2O2 + 4-Aminoantipyrine + Phenol      
POD                    Quinoneimine + 4 H2O 
Reagents 

















> 0. 2 U/mL 
> 0.1 U/mL 





Half ml of serum was transferred to the Konelab 60 Chemistry Autoanalyzer, to 
perform the test according to these parameters: 
Parameter Value 
Reagent volume (ìl) 140 
Serum volume (ìl) 2 
Calibrator 1 (mg/dl) 0.0 
Calibrator 2  CALS (mg/dl) 236 
Incubation time (s) 240 
Wavelength (nm) 510 
Calibrator type Linear 




The concentration of cholesterol test =           (A) Test   x   (C) Standard  
                                                                                (A) Standard 
 
Reference value: 
Cholesterol  200 mg/dl 
 
3.8.2 Determination of serum triacylglycerol 
 Serum triacylglycerol was determined by Glycerol phosphate oxidase/peroxidase 
method (Bucolo and David,1973). using BioSystems kit, Spain. 
Principle 
Triacylglycerol in the sample were determined by means of the coupled reactions 
described below and colored complex formed was measured photometrically 
Triglycerides + H2O      
 Lipase                Glycerol + Fatty acids 
Glycerol + ATP         Glycerol kinase             Glycerol - 3 - P + ADP 
Glycerol - 3 -P + O2       
G-3-P-oxidase      Dihydroxyacetone - P +H2O  
2H2O2 + 4- Aminoantipyrine + 4-Chlorophenol    































> 100 U/mL 
> 1.5 U/mL 
> 4 U/mL 







Half ml of serum was transferred to the Konelab 60 Chemistry Autoanalyzer, to 
perform the test according to these parameters: 
Parameter Value 
Reagent volume (ìl) 140 
Serum volume (ìl) 2 
Calibrator 1 (mg/dl) 0.0 
Calibrator 2  CALS (mg/dl) 157 
Incubation time (s) 240 
Wavelength (nm) 510 
Calibrator type Linear 




The concentration of Triacylglycerol test =           (A) Test   x   (C) Standard  
                                                                                        (A) Standard 
 
Reference value: 
Triacylglycerol   150 mg/dl 
 
3.8.3 Determination of serum high density lipoproteins  
 HDL-C was determined by precipitating method (Grove, 1979) using Lab kit, Spain. 
Principle 
 The VLDL and LDL-C from serum or plasma were precipitated by phosphotungstate 
in the presence of magnesium ions. After removed by centrifugation the clear 
supernatant contained high density lipoproteins (HDL-C) and used for its 
determination. 
Reagents 










1. Centrifuge tube 25 µl of HDL-C reagent and 250 µl serum, were mixed well and 
were allowed to stand for 10 minutes at room temperature. 
2. The mixture were centrifuged at 4000 rpm for 10 minutes then the supernatant and 
test HDL-C were collected. 
3. Centrifuge tube 1 ml cholesterol reagent and 10 µl of the supernatant, were mixed 
 Ϯϭ
well and were allowed to stand for 10 minutes at room temperature.  
4. The Unicam spectrophotometer United Kingdom, was Seted, at 505 nm and adjust 
it to zero with blank reagent. The absorbance (A) of the test was readed, and standard 
against reagent blank. 
Calculation: 
HDL Concentration =   (A) Test   x   (C) Standard 
                                               (A) Standard 
Reference value: 
HDL-C      40-60 mg/dl 
 
3.8.4 Determination of serum low density lipoproteins 
They were calculated using the empirical relationship  (Friedewald, 1972)  
Principle 
The ultracentrifugal measurement of LDL-C was time consuming and expensive and 
requires special equipment. For this reason, LDL-C was most commonly estimated 
from quantitative measurements of total and HDL-cholesterol and plasma 
triacylglycerol (TAG) using the empirical relationship of Friedewald. 
The Equation:        
       LDL-C = Total Cholesterol - HDL-C - TAG/5  
Reference value: 





3.8.5 Determination of serum C- reactive protein  
Principle 
CRP latex was used for determination of CRP in human serum (Generic assay Gmbh, 
2009). 
The CRP reagent kit was based on an immunological reaction between CRP antisera 
bound to biological inert latex particle and CRP in the test specimen. When serum 





Test tubes and rack 
Serological pipettes 
High intensity light 
Glycine saline buffer                    . 
(alternatively PBS) 





1. All reagents and samples were allowed to reach room temperature prior to testing 
then they were shaked well before use. 
2. One drop (appr 40 µl) of the positive control (P) was placed on field no.1 of the 
agglutination slide. 
3. One drop (appr 40 µl) of the negative control (N) was placed on field no.2 of the 
agglutination slide. 
 Ϯϯ
4. 40 µl of each undiluted patient sample was placed to the following field on the 
agglutination slide were used different serological pipettes. 
5. Gently resuspend the CRP latex reagent (A) and a 1 drop (40 µl) was dded to each 
test field. 
6. Mixed well with used separate stirring sticks. 
7. The slide was rocked for 2 minutes by hand or used a rocking shaker (80- 
100rpm). 
8. Immediately under direct light was readed. 
Evaluation of results 
Positive 
A positive reaction was indicated by any observable agglutination in the reaction 
mixture. The specimen reaction was compared to the CRP negative control. 
Negative 
A negative reaction was indicated by a uniform milky suspension with no 
agglutination as observed with the CRP negative control.   
3.8.6 Determination of serum leptin  
Determination of human serum leptin level was carried out by competitive enzyme 
immunoassay (Diagnostic System Laboratories (DSL). USA) technique.  
Principle 
The DSL-10-23100 ACTIVE Human Leptin ELISA is an enzymatically amplified 
"two-step" sandwich-type immunoassay. In the assay, standards, controls and 
unknown serum or plasma samples were incubated in microtitration wells, which have 
been coated with anti-human leptin antibody. After incubation and washing, the wells 
were treated with another anti-human leptin detection antibody labeled with the 
enzyme horseradish peroxidase (HRP). After a second incubation and washing step, 
the wells were incubated with the substrate tetramethylbenzidine (TMB). An acidic 
stopping solution was then added and the degree of enzymatic turnover of the 
substrate was determined by dual wavelength absorbance measurement at 450 and 
620 nm. The absorbance measured was directly proportional to the concentration of 
 Ϯϰ
human leptin present. A set of human leptin standards was used to plot a standard 
curve of absorbance versus human leptin concentration from which the human leptin 
concentrations in the sample was calculated. 
The assay procedure sheets are available with the kit, the application of assay 
procedure mentioned below.  
 
Assay procedure  
All specimens and reagents were allowed to reach room temperature (~25°C) and mix 
thoroughly by gentle inversion before use. Standards, controls and samples should be 
assayed in duplicate.  
1. The microtitration strips were marked to be used.  
2.Twenty five microlitters of the standards, controls and samples were pipeted into the 
appropriate wells.  
3. One hundred microlitters of the assay buffer E were added to each well using a 
semi-automatic dispenser.  
4. Incubated the wells, shaked at a fast speed (500-700 rpm) on an orbital microplate 
shaker, at room temperature (~25 °C) for 2 hours.  
5. Aspirated and washed each well 5 times with the wash solution using an automatic 
microplate washer. Bloted dry by inverting plate on absorbent material.  
6. The antibody-enzyme conjugate solution was prepared by diluting the antibody-
enzyme conjugate concentrate in the assay buffer.  
7. One hundred microlitters of the antibody-enzyme conjugate solution was added to 
each well using a semi-automatic dispenser.  
8. The wells were incubated, shacked at a fast speed (500-700 rpm) on an orbital 
microplate shaker, at room temperature (~25 °C) for 1 hour.  
9. Aspirated and washed each well 5 times with the wash solution using an automatic 
microplate washer. Blot dry by inverting plate on absorbent material.  
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10. One hundred microlitters of the TMB chromogen solution was added to each well 
using a semi-automatic dispenser.  
11. Incubated the wells, shaked at a fast speed (500-700 rpm) on an orbital microplate 
shaker, at room temperature (~25°C) for 10 minutes. Avoid exposure to direct 
sunlight.  
12. One hundred microlitters of the stopping solution (0.2M sulfuric acid) was added 
to each well using a semi-automatic dispenser.  
13. The absorbance of the solution in the wells was read within 30 minutes, using a 
microplate reader set to 450 nm.  
Calculation  
A. The mean absorbance for each standard, control and samples were calculated.  
B. Plot the log of the human leptin concentrations in ng/mL along the x-axis versus 
the mean absorbance readings for each of the standards along the y-axis versus, using 
a linear curve-fit. Alternatively, the data can be plotted linear vs. linear and a 
smoothed spine curve-fit can be used.  
C. Determine the human leptin concentrations of the controls and samples from the 
standard curve by matching their mean absorbance readings with the corresponding 
human leptin concentrations.  
3.9 Pilot study 
Pilot study on 10 women who had gone on OCs regimen for at least three cycles was 
carried out prior the beginning of data collection in order to test the validity and 
reliability of the questionnaire used. Comprehensive revision to it was made and 
modified as necessary. 
 
3.10 Statistical analysis 
The obtained data were analyzed by using a software statistical package for the social 
science (SPSS version 13). Frequency and descriptive analyses were used to describe 
the data. Chi square and Pearson correlation coefficient were used to test the 
relationship between the variables. Student t-test was also used to differentiate 
 Ϯϲ
between two numerical data. Any difference or correlation was considered significant 




































The present study was a case control and included 160 women (80 controls and 80 
cases). The average age ± SD of the control women was 29.8± 4.8 years whereas that 
of the cases was 29.3± 4.6 years. The control women also matched the cases in the 
residence.  
4.1 Side effects of oral contraceptives 
Table1 shows that 96.3% of the cases had regular MC, whereas 3.8% of them had 
irregular one. On the other hand,  83.8% of the controls had regular  MC, and 16.3% 
of them had irregular one. The difference among both groups with respect to nature of 
MC was statistically significantly (2=5.371, P= 0.024). 
 






Case (n=80) control (n=80) 
Parameter
Regular Irregular Regular Irregular
Frequency 77 3 67 13  





Table 2 shows that 95.0% of the cases and 100% of the controls did not suffer from 
bleeding. The difference in frequency of bleeding among both groups was not 
statistically significantly  (2=0.192, P=0.135).    
 
Table 2:  Frequency of bleeding among the study population (n=160) 
 
 
Table 3 shows that 6.3% of the cases sometimes suffer from insomnia, and 5.0% of 
them suffered from it. On the other hand, 2.5% of the  controls frequently or 
sometimes suffered from insomnia. The difference in insomnia level among the study 
population was not  statistically significant (2=0.411, P=  0.353). 
  
  Table 3:  Frequency of insomnia among the study population (n=160) 
Case (n=80)               Control (n=80)
Parameter
Yes No Sometimes Yes No Sometimes
Frequency 0 76 4 0 80 0 





Case (n=80)          Control (n=80)    
Parameter
Yes No Sometimes Yes No Sometimes
Frequency 4 71 5 2 76 2






Table 4 points out that 90.0% and 93.8%  of the cases and the controls did not suffer 
from pain in the stomach, respectively (2=0.386, P= 0.183). 
 
Table 4: Frequency of pain in the stomach among the study population (n=160) 
 
 
Table 5 illustrates  that 91.3% and 95.0 % of the cases and the controls did not suffer 
from difficulty in breathing, respectively (2=0.497, P= 0.209). 
 
Table 5: Frequency of difficulty in breathingamong the study population (n=160) 
 
 
Case (n=80)          Control (n=80)     
Parameter
Yes No Sometimes Yes No Sometimes
Frequency 3 72 5 2 75 3 




Case (n=80)   Control (n=80)   
Parameter
Yes No Sometimes Yes No Sometimes
Frequency 3 73 4 1 76 3






Table 6 points out that 78.8% and 90.0 % of the cases and the controls, respectively  
did not suffer from pain in hands and feet  (2=0.631, P= 0.309). 
 
Table 6: Frequency of pain in hands and feet among the study population (n=160) 
 
 
Table 7 shows that 16.3 % of the cases had an increase in their appetite compared to 
2.5 % of controls. The difference among the two group was statistically  significant 
(2= 4.386, P= 0.002), indicating that Ocs increase appetites. 
 
Table 7: Frequency of increasing of appetite among the study population (n=160)  
 
 
Case (n=80) Control (n=80)
Parameter 
Yes No Sometimes Yes No Sometimes
Frequency 11 63 6 6 72 2




P value 0.309 
Case (n=80) Controls(n=80) 
Parameter 
Yes No Sometimes Yes No Sometimes 
Frequency 13 59 8 2 75 3 
Percentage 16.3 73.8 10.0 2.5 93.8 3.8 

2 4.386 
P value 0.002 
 ϯϭ
Table 8 illustrates that 23.8 % of the cases suffered from headaches versus  10.0 % of 
the controls. The difference among the two groups was statistically significant (2= 
6.82, P= 0.000), indicating that OCs contributes to headaches. 
 
Table 8: Frequency of headache among the study population (n=160)  
 
 
The body mass index values of the cases and the controls are illustrated in Table 9. 
The percent of normal, overweight and obese of the cases were 22.5, 37.5 and 40.0% 
whereas among the controls the percentage were 13.8, 62.5 and 22.5% (2= 7.31, P= 
0.015). 
Table 9: Body mass index of the study population (n=160) 
People with BMI=18.524.9 were considered to have normal weight, people with BMI=25.029.9 
were classified overweight, people with BMI≥30.0 were considered obese (WHO, 2000). 
 
Case (n=80) Control (n=80) 
Parameter 
Yes No Sometimes Yes No Sometimes 
Frequency 19 49 12 8 68 4 
Percentage 23.8 61.3 15.0 10.0 85 5.0 

2 6.82 
P value 0.000 
BMI Case n (%) Control n (%) P value 
Normal 18 (22.5) 12 (13.8) 
Overweight 30 (37.5) 50 (62.5) 
Obese 32 (40.0) 18 (22.5) 





The systolic blood pressure (SBp) among the cases and the controls are illustrated in 
Table 10. The percent of cases with normal, low and high Bp were 53.8, 0.0 and 
46.3% whereas the percentage among the controls were 51.3, 2.6 and 46.3%, 
respectively. The differences between the groups were not statistically significant 
(2= 2.351, P= 0.139 ). 
 
Table 10: Systolic blood pressures among the study population (n=160) 
People with systolic blood pressure (SBp)= 110-130 mmHg  were considered to have normal Bp, 
People with SBp ! 130 mmHg considered to have high Bp, People with SBp   110 mmHg considered 













43 (53.8) 41 (51.3) 
Low Blood 
pressure 
0 (0.0) 2 (2.5) 
High Blood 
pressure 
37 (46.3) 37 (46.3) 





The diastolic blood pressures (DBp) among cases and the controls are illustrated in 
Table 11. The percent of cases with normal, low and high DBp were 88.8, 5.5 and 6.3 
whereas the percentages among the controls were 88.8, 6.3 and 5.1, respectively (2= 
1.372, P= 0.382 ). 
 
Table 11: Diastolic blood pressure among the study population (n=160) 
People with diastolic blood pressure (DBp)= 75-85 mmHg were considered to have normal Bp, People 
with DBp! 85  mmHg considered to have high Bp, People with SBp   75 mmHg considered to have 









Diastolic  blood 




71 (88.8) 71 (88.8) 
Low Blood 
pressure 
4 (5.5) 5 (6.3) 
High Blood 
pressure 





4.2 Some biochemical parameters and oral contraceptives 
4.2.1 C- reactive protein 
Table 12 shows that 13.8of the cases had positive CRP test compared to 5.0 of 
the controls.  The difference among the two groups was statistically significant (2= 
5.381, p= 0.034). 
 
Table 12: C-reactive protein test among the study population 
 
 
4.2.2 Lipid profile 
As depicted from Table 13, the average levels ± SE of serum cholesterol, and LDL-C 
were significantly higher among the cases (179.1± 4.3, and 97.6±4.0 mg/dl) compared 
to the controls (157.5± 4.1 and 86.2± 3.4 mg/dl). The differences among the study 
population with respect to cholesterol level were very significant (p= 0.000 and p= 
0.002, respectively). The mean values ± SE of HDL-C and TAG slightly increased 
among the cases (51.2±1.7 and 119.2± 6.0 mg/dl) compared to the  controls (47.6±1.3 
and 108.2± 8.6 mg/dl). These changes in HDL-c and TAG among the study 
population were not significant (p=0.148 and p=0.218, respectively).  
 
 
Case (n=80) Control (n=80) 
Parameter 
Positive Negative Positive Negative 
Frequency 11 69 4 67 
Percentage 13.8 86.3 5.0 95.0 

2 5.381 
P value 0.034 
 ϯϱ
Table 13: Lipid profile among the study population (n=160) 
S.E: standard error, HDL-c: high density lipoprotein cholesterol, LDL-c: low density lipoprotein  
cholesterol. Reference range: cholesterol<200 mg/dl, LDL-C<130 mg/dl, triglyceride 90-150 mg/dl 
(Mark Cichocki, 2007), HDL-C=40-60 mg/dl (Richard and Fogoros, 2009). 
 
4.2.3 Leptin analysis 
Table 14 shows average ± SE serum leptin level among the study population. There 
was a significant increase in the mean level of leptin among the cases compared to the 
controls (36.3± 2.3 ng/ml vs. 28.6± 2.1 ng/ml, and p= 0.003). 
 
Table 14: Serum leptin level among the study population (n=160) 







Case (n=80) Control (n=80)  Lipid Profile 
(mg/dl) Mean S.E Mean S.E T 
 
P value 
Cholesterol 179.1 4.3 157.5 4.1 3.647 0.000 
HDL-C 51.2 1.7 47.6 1.3 1.700 0.148 
LDL-C 97.6 3.8 86.2 3.4 2.238 0.002 
Triglycerides 119.2 6.0 108.2 8.6 1.047 0.218 
Case (n=80) Control (n=80)  Parameter 






36.3 2.3 28.6 2.1 2.459 0.003 
 ϯϲ
4.2.4 Lipid profile, BMI and leptin 
Table 15 shows a positive correlation between leptin level and BMI. This correlation 
was statistically significant ((r=0.445, p=0.000). On the other hand no significant 
corrrelations were observed between leptin and cholesterol or HDL-C or LDL-C or 
TAG (p=0.843, p=0.300, p= 0.252 and   p=0.397, respectively). 
 
Table 15: The correlation between leptin and lipid profile of the group study 
Leptin  
Parameter Pearson correlation 
(r)  
P-value  
Cholesterol (mg/dl) 0.023 0.843 
HDL-C (mg/dl) 0.177 0.300 




BMI 0.445 0.000 
 
 
4.3 Complete blood count analysis 
The tested CBC parameters are illustrated in the table 16. The average ± SE levels of 
WBC, Gran and Mch were significantly higher among the cases (7.2±2.1 K/µL, 
60.7±8.3 % and 26.9±2.2pg) compared to the controls (6.6±1.7 K/µL, 54.9±11.7 % 
and 25.7±3.433 pg) with p=0.001, p=0.000 and p=0.003, respectively. The mean ± SE 
of Lymph and RDW were decreased among the cases (32.4±7.3% and 13.4±1.2%) 
compared to the controls (36.3±7.8% and 14.2±1.5%). These changes were also 
highly significant (p=0.002 and p=0.001). However, the changes among the study 
population in Mid, RBc,  Hb, Hct, Mcv, Mchc and PLt  were not significant. 
 
 ϯϳ
Table 16: Screening of blood count parameters among the study population (n=160) 
WBC: White blood count; Lymph: Lymphocytes; Gran: granulocytes, types of white blood cells; MID 
cells include less frequently occurring and rare cells correlating to monocytes, basophils: blasts and 
other precursor white cells; RBC: Red blood cells; Hb. The hemoglobin; HCT: Hematocrit MCV: mean 
cell volume; MCH: mean cell hemoglobin; and MCHC: mean cell hemoglobin concentration; RDW. 











Case Control Blood 
parameter Mean SD Mean SD 
T P value 
WBC (K/µL) 7.2 2.1 6.6 1.7 2.065 0.001 
Lymph (%) 32.4 7.3 36.3 7.8 3.233 0.002 
Mid (%) 7.8 8.7 8.6 6.6 0.659 0.352 
Gran (%) 60.7 8.3 54.9 11.7 3.580 0.000 
RBC (M/µL) 4.6 0.7 4.6 0.4 0.558 0.394 
Hb ( g/dL) 12.2 0.9 12.3 1.1 0.457 0.387 
Hct (%) 38.0 2.49 37.5 3.7 0.967 0.571 
MCV (fL) 80.8 12.0 80.6 8.5 0.094 0.415 
MCH (pg) 26.9 2.29 25.7 3.4 2.542 0.003 
MCHC (g/dl)  32.5 1.1 32.3 1.7 0.852 0.272 
RDW (%) 13.4 1.2 14.2 1.5 3.681 0.001 




Oral contraceptives provide highly reliable contraceptive protection. Even though 
imperfect use (skipping an occasional pill) is considered, the OCs are still very effective 
in preventing pregnancy. This case control study is the first one to determine some risk 
factors of having OCs among healthy women in Gaza City.  
 
5.1 Oral contraceptives and nature of menstrual cycle 
The study showed that OCs increased regularity of MC. This finding was very consistent 
with other studies which showed that OCs  are helpful for women periods that come too 
often or too late. Menstrual periods tend to be lighter and shorter with OCs intake and  the 
timing of a period can be controlled (Women's Health, 2009). Regular MC and less blood 
loss is helpful in preventing anemia. 
 
5.2 Oral contraceptives and an increase of appetite 
The results showed that continuous OCs intake as anabolic hormone lead to an increase in 
appetite where there was significant difference among both study groups with respect to 
this parameter and high BMI. Thus, an increase in appetite led to an increase in body 
weight. It was shown that both estrogen and progesterone present in OC pills can cause 
fluids and salt (sodium) retention (Crystal, 2005).  
  
5.3 Oral contraceptives and headache 
The findings showed that there was significant difference with respect to feeling of 
headache  among both study groups. Thus, frequent use of steroid hormones could cause 
headaches. The exact relationship between OCs and headache is unclear (Hormonal 
Headaches, 2010). This finding was consistent with other studies which showed that most 
women who were went on OCs suffer from migraines headaches (Wilson, 2006).  
 ϯϵ
In addition, this finding was in agreement with other studies showed that OCs caused 
headache activity among most women during early cycles of OCs use and disappeared 
with continued use (Loder et al., 2005). 
 
5.4 Oral contraceptives and body weight 
The results showed that significant difference among both study groups with respect to 
BMI. Body mass index is an indirect method to determine body fat that accumulates in 
the body if energy input was higher than energy output. These findings were very 
consistent with the finding that OCs intake increased an appetite and abnormal high 
concentrations of serum lipids among women (Reubinoff et al., 1995).  A survey of 
women in the United Kingdom reported that nearly three in four believed that weight gain 
was associated with oral contraceptive use. A study of US adolescents found that, overall, 
45% were very concerned about the potential for weight gain while taking OCs (86% 
among suburban teens). A similar survey of Canadian teens reported more than half had 
heard that OC use causes weight gain. (The Contraception Report, 2001).Weight gain 
might be also related to a reduction in physical activity. Progesterone, however,  in the 
OCs causes an increase  in an appetite, and fat deposits. Nevertheless, obese women 
should look for another method of contraceptive.  
  
5.5 Oral contraceptives and lipid profile 
The results showed that there were significant differences among both study groups with 
respect to total cholesterol and LDL-c levels in the blood. However, a sgnificance 
difference among both groups with respect to TAG level in the blood was not observed. 
This finding about the effect of OCs on cholesterol have been reported before (Parks et 
al., 1989). Thus, women who are going on OCs regime are more vulnerable to suffer from 
cardiovascular diseases such as heart attack, stroke, atherosclerosis etc. (Birth Control 
Pills Advantages and Disadvantages, 2007). However other studies emphasized that the 
chances of OCs contributing to a heart attack are small unless you smoke (Women's 
Health, 2004). Doar et al., (1969) reported that OCs were associated with significantly 
raised mean serum TAG and TC levels. In addition, Hennekens et al., (1979) reported 
that, the mean level of fasting TAG was higher among current OC users than among 
 ϰϬ
nonusers. After adjustment for the possible confounding effects of age, weight, current 
cigarette smoking and fasting glucose level, current OC users still had higher TAG blood 
level than that of nonusers. 
Moreover, Parks et al., (1989) observed that OC pills increased TC and TAG 
concentrations in the blood. Statistically significant increases were observed for TAG, 
LDL-c, and VLDL-c with the duration of OCs use (Emokpae et al., 2010). 
  
5.6 Oral contraceptive and blood pressure:  
The study showed that readings of SBp and DBp remained within the normal range 
among OCs women. It seemed that an increase in LDLs level among the study group 
could not lead to precipitation of cholesterol on artery  walls. Early results from a 
controlled long-term prospective study have shown no significant change in mean systolic 
or diastolic pressures or mean weight in women after four months on OCs. However,  
there was a significant change in Bp over the short period of the experiment (Weir et al., 
1969).In contrast to the present finding, Calvin et al., (1969) revealed slightly higher and 
statistically significant mean SBp and DBp in women using OCs, after correction for age, 
height, weight, and arm circumference. One year later, they showed little tendency for Bp 
to be affected by OCs.  Moreover, Fisch et al., (1977) study showed rise in mean Bp. The 
age-adjusted proportion of OCs users with a Bp over 140/90 mm Hg was about three 
times that of nonusers. This effect is possibly mediated by the estrogen-induced activation 
of the renin-angiotensin system. Oral contraceptives also appear to increase the tubular 
responsiveness to changes in sodium intake. This indicated that synthetic sex steroids 
have a significant impact on renal function in women (Bertschi et al., 2003). These results 
should not prevent continuous monitoring of BP for several months after the woman start 
taking OCs. 
 
5.7 Oral contraceptives and serum leptin level 
The results showed that there were significant difference among both study groups with 
respect to leptin. Body fat is responsible for release of leptin. Positive correlation between 
serum leptin and BMI was also found Thus, intake increased an appetite and thus, body 
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fat and leptin level. In contrast to out results, statistical analysis of other study, did not 
reveal any significant difference at each investigated time point in either study group with 
respect to serum leptin or BMI (Rechberger et al., 1999). This contradiction between both 
studies could be attributed to type of OCs pills or sample size used. 
      .                       .                                            .                            
5.8 Oral contraceptives and C- reactive protein 
C-reactive protein (CRP) increases when blood vessels become inflamed. According to 
the present results, there was significant difference among both study groups with respect 
of CRP. It seemed that OCs affected liver functions in such a way which leaded to an 
increase in C-reactive protein blood level. This finding was consistent with recent cross-
sectional survey which demonstrated that CRP levels are significantly increased among 
OC users versus non-users (Krupa., 2003). Other studies showed that more than 50 % of 
apparently healthy women taking OCs had CRP levels >3 mg/l (Rietzschel et al., 2007). 
These findings indicated that OC pills could cause high-risk of inflammation and thus, 
could activate immune response. 
                                                   .                                                                           
5.9 Oral contraceptives and complete blood count 
5.9.1 Oral contraceptives and white blood cells 
The results showed significant increase in WBC of cases compared to controls. This 
increase reflected that OCs could cause some type of internal infection among the 
women. Moreover, the increase in Gran (%) among the study group could reflect this type 
of infection to be bacterial. In contrast, the case group showed a significant decrease in 
lymphocytes and this contradiction requires further investigation. 
 This finding was consistent with an other study which showed that smoking and OCs use 
are factors that alter WBC count among healthy women. However, a total leukocyte count 
greater than 10,000/cu mm was found in 44% of obese, heavily smoking women who 




5.9.2 Oral contraceptive and mean cell hemoglobin 
The finding showed that there was significant differences among study groups with 
respect to Mch and RDW. An increase in MCH could reflect anemia of chronic diseases. 
In contrast, the slight decrease in RDW could reflect change in internal iron level among 






















Conclusions and Recommendations 
 
6.1 Conclusions 
 Frequent use of OCs could cause regulation of menstrual cycle, increase 
appetite, feeling of headaches as well as increases in BMI, cholesterol, LDL-C, 
and Leptin.  
 Frequent use of OCs could not affect bleeding, frequency of insomnia, 
stomachache, difficulty in breathing, frequency of pain in hands and feet, SBp, 
DBp, HDL-c , and TAG.       
 There was strong correlation between BMI and leptin among the case study . 
 Frequent use of OCs  could cause significant increase in WBC, Gran, and MCH 














 The risk factors of OCs intake such as increase in appetite, body fat composition, 
blood fats and modifying immune system, should be taken in consideration and 
required integrated relevant interventions. 
 More awareness sessions on health eating pattern for mothers who are going on 
OCs should be implemented in schools, audio-vision systems, and local 
organizations 
 Monitoring body weight as well as biochemical examinations must be carried out 
monthly for every OCs woman.  
 More deep and screening research studies about the effect of OCs intake on some 
other anabolic steroid hormones and heat generating hormones such as thyroid 
ones could be addressed and conducted by higher level of responsibility from 
Ministry of health (MOH) in cooperation with universities in Gaza strip. 
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